Bristol-Myers Squibb Seminar in Organic Chemistry: Novel PET radioligands for non-invasive imaging of the PD-1/PD-L1 immune checkpoint pathway
Seminar | May 1 | 4-5 p.m. | 775 Tan Hall
David Donnelly, Senior Research Investigator, Bristol-Myers Squibb
David J. Donnelly completed his Ph.D. in Organic Chemistry in 2006 from the University of Buffalo with a focus on the synthesis of sulfur, selenium and tellurium containing rhodamine dyes for use in photodynamic therapy. After receiving his Ph.D. he conducted his post-doctoral research with Professor Mike Kilbourn at the University of Michigan, where he worked on the synthesis and design of both carbon-11 and fluorine-18 PET radioligands for in-vivo PET imaging. During his post-doctoral studies he completed the synthesis of more than 20 different PET radioligands for human use such as: 11C-PIB, 11C-Carfential, and 18F-Florbetapir to name a few. David joined BMS in 2007 where his research has been focused on the design and synthesis of PET radioligands for use in both drug discovery and drug development process at BMS. He has recently been involved with the discovery and development of 5 different PET radioligands that have been used in human imaging to better understand the fundamental biology of cancer and fibrosis targets. These tracers include the first LPA1 human lung tracer (11C-BMT-136088) and 18F-BMS-986192 a novel PET radioligand used in human lung tumor imaging studies of the PD-L1 receptor. David has received several distinguished awards at BMS, including the 2016 Chemistry leadership award and the 2017 Ondetti/Cushman award, which is the highest R&D award at BMS. David has contributed to 17 publications and 8 patents.